APH
Amphenol Corporation
APH's outlook is improving, though it still trails on the overall score.
NVDA
NVIDIA Corporation
NVDA has the edge over APH overall, supported by stronger valuation and stronger modeled upside.
APH Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Healthy |
APH's revenue, profitability, cash flow and balance sheet are all currently healthy.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
APH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 23x | $79.62 | — |
| Cheap | 26x | $60.41 | -24% |
| Fair | 33x | $76.08 | -4.4% |
| Current | 35x | $79.62 | — |
| Expensive | 42x | $96.05 | +21% |
Historical ranges are pointers, not guarantees.
APH's PE is in its fair range at 35x. If earnings grow as analysts expect, today's price would be 23x next year's earnings, in its cheap range.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA has the edge over APH in the historical PE scenario, which offers more potential upside but is not a forecast.
APH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Improving | |
| Limited | |
| High |
APH has the edge over NVDA on the outlook, with more favorable profitability expectations.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
APH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.46 | +50% |
| Q3 2026 | $2.30 | +53% |
| Q2 2026 | $1.99 | +58% |
| Q1 2026 | $1.74 | +69% |
| Q4 2025 | $1.67 | +74% |
| Q3 2025 | $1.50 | +72% |
| Q2 2025 | $1.26 | +50% |
| Q1 2025 | $1.03 | +26% |
| Q4 2024 | $0.96 | +23% |
APH's earnings per share have climbed steadily: $2.30 over the past year, up 53% from the year before, and higher year over year every quarter since late 2020.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over APH on earnings, with stronger typical year-over-year growth.
APH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $10.2B | +65% |
| Q2 2026 | $8.8B | +55% |
| Q1 2026 | $7.6B | +58% |
| Q4 2025 | $6.4B | +49% |
| Q3 2025 | $6.2B | +53% |
| Q2 2025 | $5.7B | +57% |
| Q1 2025 | $4.8B | +48% |
| Q4 2024 | $4.3B | +30% |
APH's revenue has grown year over year for 12 quarters in a row: $10.2B last quarter, up 65% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | +2.1 points |
| Q2 2026 | 30% | +4.4 points |
| Q1 2026 | 24% | +2.7 points |
| Q4 2025 | 27% | +4.7 points |
| Q3 2025 | 27% | +7.2 points |
| Q2 2025 | 25% | +5.8 points |
| Q1 2025 | 21% | +0.3 points |
| Q4 2024 | 22% | +1.4 points |
APH's operating margin was 30% last quarter, up 2.1 points from the same quarter a year ago, near the top of its range since 2019.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over APH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over APH on profitability, with a higher operating margin.
APH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.6B | +34% |
| Q2 2026 | $1.2B | +7.3% |
| Q1 2026 | $829.9M | +44% |
| Q4 2025 | $1.5B | +127% |
| Q3 2025 | $1.2B | +156% |
| Q2 2025 | $1.1B | +114% |
| Q1 2025 | $576.3M | +14% |
| Q4 2024 | $647.3M | -12% |
APH's free cash flow has been positive every quarter for seven years: $5.1B over the past year, up 44% from the year before.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over APH on cash flow, with stronger typical year-over-year growth.
APH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +4.5M shares |
| 1 year | +0.7% | +17.3M shares |
| 3 years | +3.8% | +94.9M shares |
| 5 years | +3.2% | +79.7M shares |
| Available history | +4.9% | +120M shares |
APH has 2.6B diluted shares, up 0.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $244.6M |
| Q2 2026 | $208M |
| Q1 2026 | $178M |
| Q4 2025 | $171.3M |
| Q3 2025 | $152.9M |
| Q2 2025 | $160.1M |
| Q1 2025 | $180.9M |
| Q4 2024 | $168.9M |
APH spent $802M buying back its own shares over the past year, up 21% from the year before.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has the edge over APH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
APH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.3x | Healthy |
| Q2 2026 | 1.5x | Healthy |
| Q1 2026 | 1.9x | Healthy |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.7x | Very low |
| Q2 2025 | 1.0x | Very low |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.0x | Very low |
APH's net debt is about 1.3 years of its operating earnings (EBITDA), up from less than a year a year ago.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA has the edge over APH on leverage, with a lower net debt burden relative to earnings.
APH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.6 | Neutral |
| Stochastic | 36.3 | Neutral |
APH's weekly RSI is 52 (neutral) and its Stochastic is 36 (neutral).
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
APH PE vs Technology Sector
| Metric | APH | Sector median | Relative |
|---|---|---|---|
| PE | 35x | 28x | 24% above |
| PE % | 59 | 35 | 24 pts above |
APH is trading at 35x earnings, a 24% premium to the Technology sector's median of 28x.
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA has the edge over APH on valuation relative to its sector.
APH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $80.7 | 1.3% below |
| 20 week MA | $80.5 | 1% below |
| 50 week MA | $74.5 | 6.9% above |
| 100 week MA | $60.8 | 31% above |
| 200 week MA | $43.4 | 83% above |
APH has the edge over NVDA on trend strength, trading above more of its moving averages.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has fallen below most of its moving averages, though it's still 34% above its 200-week average.
APH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.5 | $16.2 | +20% |
| 2021 | $16.2 | $21.3 | +32% |
| 2022 | $21.3 | $19.0 | -11% |
| 2023 | $19.0 | $24.8 | +31% |
| 2024 | $24.8 | $35.4 | +43% |
| 2025 | $35.4 | $68.7 | +94% |
| 2026 YTD | $68.7 | $79.6 | +16% |
APH has the edge over NVDA on returns for 2026, with the stronger performance.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA's yearly returns have swung widely, from +226% in 2023 to −49% in 2022. It's down 13% so far in 2026.